Pharmaceutical Pipeline

Selected Pharmaceuticals in Late Stage U.S. and E.U. Development or Registration as of July 21, 2021

RYBREVANT Infectious Diseases and Vaccines Newly Added

0 of 53 Total Indications

This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. (2) aprocitentan developed in collaboration with Idorsia; (3) XARELTO co-developed with Bayer HealthCare; (5) DARZALEX licensed from Genmab A/S; (6) IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company; (7) BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; (8) Niraparib licensed from Tesaro; (9) BCMA CAR-T licensed from Legend Biotech; (10) Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; (11) DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab);